Test drug HS-20093 for osteosarcoma after earlier treatment
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- Your osteosarcoma or sarcoma must be confirmed by pathology and have returned or progressed after first standard chemotherapy
- You need at least one measurable tumor spot that can be measured on scans
- You must be able and willing to give new or saved (archival) tumor tissue and blood samples
- You should be well enough to do most daily activities (ECOG score 0–1) and expected to live at least 12 weeks
- You must use reliable birth control and, if you can become pregnant, you must not be pregnant at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.